Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Rigel Pharmaceutical (RIGL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 392,871
  • Shares Outstanding, K 167,179
  • Annual Sales, $ 44,510 K
  • Annual Income, $ -70,480 K
  • 60-Month Beta 1.28
  • Price/Sales 8.45
  • Price/Cash Flow N/A
  • Price/Book 3.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.13
  • Number of Estimates 3
  • High Estimate -0.12
  • Low Estimate -0.14
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.17 +5.99%
on 04/23/19
2.62 -12.21%
on 04/01/19
-0.15 (-6.12%)
since 03/22/19
3-Month
2.00 +15.00%
on 03/01/19
2.68 -14.18%
on 03/21/19
+0.21 (+10.05%)
since 01/24/19
52-Week
1.96 +17.35%
on 12/26/18
4.12 -44.17%
on 05/18/18
-1.43 (-38.34%)
since 04/24/18

Most Recent Stories

More News
Rigel Welcomes Jane Wasman to Board of Directors

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of experience in the biopharma...

RIGL : 2.30 (-2.13%)
Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.

RIGL : 2.30 (-2.13%)
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2018 financial results after market close on Thursday, February 28, 2019. Rigel senior management...

RIGL : 2.30 (-2.13%)
Rigel Pharmaceuticals Provides Business Update

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, including the quantity of TAVALISSE(TM) bottles sold in 2018 and its cash position as of December 31, 2018, as well as an overview...

JPM : 113.55 (-0.17%)
RIGL : 2.30 (-2.13%)
Do Options Traders Know Something About Rigel Pharmaceuticals (RIGL) Stock We Don't?

Investors need to pay close attention to Rigel Pharmaceuticals (RIGL) stock based on the movements in the options market lately.

RIGL : 2.30 (-2.13%)
Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 37th Annual J.P. Morgan Healthcare Conference...

JPM : 113.55 (-0.17%)
RIGL : 2.30 (-2.13%)
Rigel: 1Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $24.4 million in its first quarter.

RIGL : 2.30 (-2.13%)
Rigel Announces First Quarter 2018 Financial Results and Provides Company Update

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the first quarter ended March 31, 2018.

RIGL : 2.30 (-2.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade RIGL with:

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

2nd Resistance Point 2.42
1st Resistance Point 2.36
Last Price 2.30
1st Support Level 2.25
2nd Support Level 2.20

See More

52-Week High 4.12
Fibonacci 61.8% 3.29
Fibonacci 50% 3.04
Fibonacci 38.2% 2.79
Last Price 2.30
52-Week Low 1.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar